This kit is designed for the rapid and specific detection of residual E1A & SV40LTA DNA derived from host cell (e.g., HEK293 cell) in biological products.
This kit adopts the fluorescent probe method and multiplex PCR method. The kit is a rapid, specific and reliable device, with the minimum detection limit reaching 40copies/μL.
| Specification | 100 Reactions |
Assay range | 4×101 ~4×106copies/μL |
Limit of quantitation | 4×101copies/μL |
Precision | CV%≤15% |
| Validity period | 18 months |
| Storage conditions | -20℃ |
| LOQ | 20 copies/μL |
| LOD | 2 copies/μL |
| IND Filing | OK |
| Concentration (copies/μl) | Log10 Concentration | Ct Value(1) | Ct Value(2) | Ct Value(3) | Ct Mean Value | CV |
| 4.00E+06 | 6.60 | 15.15 | 15.14 | 15.04 | 15.11 | 0.40% |
| 4.00E+05 | 5.60 | 18.51 | 18.63 | 18.40 | 18.51 | 0.63% |
| 4.00E+04 | 4.60 | 21.66 | 21.70 | 21.71 | 21.69 | 0.12% |
| 4.00E+03 | 3.60 | 25.04 | 24.51 | 25.11 | 24.89 | 1.32% |
| 4.00E+02 | 2.60 | 27.48 | 27.75 | 27.25 | 27.49 | 0.91% |
| 4.00E+01 | 1.60 | 31.30 | 31.18 | 31.17 | 31.22 | 0.24% |
| Amplification efficiency | 107.2% | |||||
Standard curve:
1-805-304-6109 
info@hillgene.com 
English
![Hillgene Was Awarded the TOP 10 Most Promising CXO Companies of [China Biopharmaceutical Industry in 2022]](/uploads/image/20250530/hillgene-was-awarded-the-top-10-most-promising-cxo-companies-of-china-biopharmaceutical-industry-in-2022.webp "Hillgene Was Awarded the TOP 10 Most Promising CXO Companies of [China Biopharmaceutical Industry in 2022]")
